These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2973361)

  • 1. Allogeneic bone marrow transplantation in multiple myeloma: a report of four cases.
    Nikoskelainen J; Koskela K; Kätkä K; Pelliniemi TT; Kulmala J; Salmi T; Toivanen A
    Bone Marrow Transplant; 1988 Sep; 3(5):495-500. PubMed ID: 2973361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic bone marrow transplantation for multiple myeloma.
    Tura S; Cavo M; Rosti G; Bandini G; Gobbi M; Grimaldi M; Miggiano MC; Albertazzi L; Bonelli MA
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():106-8. PubMed ID: 2697418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission.
    Byrne JL; Fairbairn J; Davy B; Carter IG; Bessell EM; Russell NH
    Bone Marrow Transplant; 2003 Feb; 31(3):157-61. PubMed ID: 12621475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy does not nullify the ability of donor lymphocyte infusions to mediate graft-versus-host reactions.
    Fuchs EJ; Seber A; Altomonte V; Braine HG; Humphrey RL; Jones RJ; Noga SJ; Schepers K; Wright SK; Vogelsang GB
    Bone Marrow Transplant; 1998 Aug; 22(3):303-5. PubMed ID: 9720749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes.
    Mattijssen V; Schattenberg A; Schaap N; Preijers F; De Witte T
    Bone Marrow Transplant; 1997 Apr; 19(8):791-4. PubMed ID: 9134170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Allogenic bone marrow transplantation in multiple myeloma. Analysis of 12 consecutive cases].
    Bladé J; Carreras E; Rozman C; Sierra J; Rovira M; Batlle M; Valls A; Algara M; Marín P; Urbano-Ispizua A
    Med Clin (Barc); 1995 Jun; 105(1):1-4. PubMed ID: 7637408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Allogeneic bone marrow transplantation for refractory multiple myeloma: presence of a graft-versus-myeloma effect].
    Nawa Y; Noguchi T; Kojima K; Hara M
    Rinsho Ketsueki; 2001 Jun; 42(6):481-7. PubMed ID: 11505527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of previous high-dose therapy on outcome after allografting for multiple myeloma.
    Kulkarni S; Powles RL; Treleaven JG; Singhal S; Saso R; Horton C; Killick S; Tait D; Ramiah V; Mehta J
    Bone Marrow Transplant; 1999 Apr; 23(7):675-80. PubMed ID: 10218843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy of multiple myeloma by allogeneic bone marrow transplantation].
    Heyll A; Aul C; Söhngen D; Meckenstock G; Arning M; Wurm R; Schmitt G; Schneider W
    Dtsch Med Wochenschr; 1991 May; 116(22):852-6. PubMed ID: 1903693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update of prognostic factors for allogeneic bone marrow transplantation in multiple myeloma using matched sibling donors. European Group for Blood and Marrow Transplantation.
    Gahrton G; Tura S; Ljungman P; Bladé J; Cavo M; De Laurenzi A; Façon T; Gratwohl A; Michallet M; Nikoskelainen J
    Stem Cells; 1995 Aug; 13 Suppl 2():122-5. PubMed ID: 8520500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors.
    Demuynck H; Verhoef GE; Zachee P; Emonds MP; van der Schueren E; van den Berghe H; Vandenberghe P; Casteels-Van Daele M; Boogaerts MA
    Bone Marrow Transplant; 1996 May; 17(5):745-51. PubMed ID: 8733692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
    Reynolds C; Ratanatharathorn V; Adams P; Braun T; Silver S; Ayash L; Carson E; Eisbruch A; Dawson LA; McDonagh K; Ferrara J; Uberti J
    Bone Marrow Transplant; 2001 Apr; 27(8):801-7. PubMed ID: 11477436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discrepancy between serological complete remission and concomitant new bone lytic lesions after infusion of escalating low doses of donor lymphocytes in multiple myeloma: a case report.
    Rondelli D; Bandini G; Cavo M; Re F; Motta M; Senese B; Leopardi G; Stanzani M; Tura S
    Bone Marrow Transplant; 1999 Sep; 24(6):685-7. PubMed ID: 10490737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma.
    Cavo M; Bandini G; Benni M; Gozzetti A; Ronconi S; Rosti G; Zamagni E; Lemoli RM; Bonini A; Belardinelli A; Motta MR; Rizzi S; Tura S
    Bone Marrow Transplant; 1998 Jul; 22(1):27-32. PubMed ID: 9678792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
    Giralt S; Aleman A; Anagnostopoulos A; Weber D; Khouri I; Anderlini P; Molldrem J; Ueno NT; Donato M; Korbling M; Gajewski J; Alexanian R; Champlin R
    Bone Marrow Transplant; 2002 Sep; 30(6):367-73. PubMed ID: 12235521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous bone marrow mixed with HLA-haploidentical allogeneic marrow transplantation for treatment of patients with malignant blood diseases.
    Da WM; Liu Y; Zhong JT; Bai H; Ji MJ; Wang CB; Lu JZ; Chen JM; Wang YL; Wu XX; Xu SF; Zhang Q; Wei YM
    Bone Marrow Transplant; 1997 Jan; 19(2):107-12. PubMed ID: 9116606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.
    Orsini E; Alyea EP; Schlossman R; Canning C; Soiffer RJ; Chillemi A; Neuberg D; Anderson KC; Ritz J
    Bone Marrow Transplant; 2000 Mar; 25(6):623-32. PubMed ID: 10734296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.